Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imiquimod vs PDT for Actinic Keratoses in Organ Transplant Recipients
NCT01538901Phase 4Terminated
- Sponsor
- Medical University of Vienna
- Start
- Sep 2012
- Primary completion
- Sep 2014
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of methyl aminolevulinate in actinic keratosis (AK) (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Clinical complete response rate at 4 weeks. Started Sep 2012; status: terminated.
02
Drugs
methyl aminolevulinate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT01538901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01538901.